Sign In
Buy BEAM
$25.52
-0.97 (-3.66%)
At Close: Jul 31, 2026
CAMBRIDGE, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the
Beam Therapeutics Inc. (NASDAQ:BEAM) Given Average Rating of “Moderate Buy” by Brokerages
02:15am, Thursday, 23'rd Jul 2026
Beam Therapeutics Inc. (NASDAQ: BEAM - Get Free Report) has received an average recommendation of "Moderate Buy" from the fourteen ratings firms that are presently covering the company, MarketBeat rep
Amova Asset Management Americas Inc. Has $91.16 Million Stock Holdings in Beam Therapeutics Inc. $BEAM
03:14am, Tuesday, 21'st Jul 2026
Amova Asset Management Americas Inc. lowered its stake in Beam Therapeutics Inc. (NASDAQ: BEAM) by 13.2% during the first quarter, according to its most recent 13F filing with the Securities and Excha
Cathie Wood Is Buying This Up-and-Coming Biotech Stock. Should You Follow Her Lead?
01:30pm, Monday, 20'th Jul 2026
Beam Therapeutics' growing pipeline could reward patient investors.
Prime Medicine Beats Beam Therapeutics In Patent Dispute - But Both Are Investable
10:22am, Thursday, 09'th Jul 2026
Prime Medicine, Inc. secured a favorable arbitration ruling against Beam Therapeutics, allowing continued development of its PM647 gene editing program for AATD. PRME's Prime Editing platform offers p
Prime Medicine Secures Favorable Arbitration Ruling in Beam Therapeutics Case
01:29pm, Wednesday, 08'th Jul 2026
Prime Medicine Inc. (NASDAQ:PRME) said it secured a favorable, binding arbitration ruling in its dispute with Beam Therapeutics Inc. (NASDAQ:BEAM).
A New CRISPR "DNA Shredder" Could Change Gene-Editing -- What It Means for CRISPR Therapeutics
05:45am, Wednesday, 08'th Jul 2026
Gene-editing is a handy tool for developing sophisticated medicines. A new CRISPR molecule can destroy cells that express specific signals.
Powder Keg Stocks: 10 Most‑Shorted Names Primed For A Monster Squeeze
10:35am, Monday, 29'th Jun 2026
Fresh short‑interest data for late June shows a tightly packed group of mid‑ and large‑cap names where bearish positioning has reached extreme territory, setting the stage for violent moves if s
BEAM Stock Gains 5% as FDA Clears BEAM-304 IND for Phenylketonuria
11:36am, Friday, 19'th Jun 2026
Beam Therapeutics gains after the FDA clears the IND for BEAM-304 in PKU, advancing its liver-targeted gene-editing program into clinical testing.
BEAM-304 Development Approach Has Potential to Create Transformative, One-time Therapies for the Majority of Patients with PKU BEAM-304 Program Designed as Platform-based Approach Reflecting Emergin
The Healthcare M&A Wave
12:30pm, Wednesday, 17'th Jun 2026
In this week's edition of InnovationRx, we look at biotech M&A, the rise of India's Anthem Biosciences, and more. To get it in your inbox, subscribe here.
Beam Therapeutics Stock Soars 21% in Three Months: Here's Why
09:51am, Tuesday, 16'th Jun 2026
BEAM shares jump 21% in three months as promising BEAM-302 data, pipeline milestones and a cash runway into mid-2029 boost investor confidence.
3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2026
01:10pm, Tuesday, 02'nd Jun 2026
Genomics and synthetic biology are reshaping healthcare, with growing demand for precision medicine spotlighting stocks like PACB, MYGN and TWST.
Beam Therapeutics Inc. (BEAM) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
01:37pm, Monday, 25'th May 2026
Beam Therapeutics Inc. (BEAM) Presents at RBC Capital Markets Global Healthcare Conference 2026 Transcript
Beam Therapeutics Eyes Sickle Cell BLA as Alpha-1 Gene-Editing Program Advances
02:05pm, Wednesday, 20'th May 2026
Beam Therapeutics NASDAQ: BEAM Chief Executive Officer John Evans said the company is advancing its base-editing platform across hematology and liver disease programs, with a potential biologics licen
